ENDPOINTS

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

Plus, news about Odyssey Therapeutics, GSK, Aligos Therapeutics, Terrain Biosciences, the Gates Foundation and Neuphoria Therapeutics: Biogen appears to back away from dealmaking projections: The company’s execs faced questions about dealmaking capacity during the fourth ...

Feb 12, 2025 - 19:42
 0
Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet
Plus, news about Odyssey Therapeutics, GSK, Aligos Therapeutics, Terrain Biosciences, the Gates Foundation and Neuphoria Therapeutics: Biogen appears to back away from dealmaking projections: The company’s execs faced questions about dealmaking capacity during the fourth ...
Read More

Tags:

Previous Article

Gourmet cockatoos like to fancy up their food

Next Article

Top N.I.H. Official Abruptly Resigns as Trump Orders Deep Cuts

Related Posts

SpringWorks lands FDA approval for nerve tumor treatment

SpringWorks lands FDA approval for nerve tumor treatment

Feb 12, 2025  0

AstraZeneca cuts UK funding pledge; Viking says it has ‘enough’ API for trials

AstraZeneca cuts UK funding pledge; Viking says it has ...

Feb 9, 2025  0

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Novartis returns for its anticoagulant in up to $3.1B b...

Feb 11, 2025  0